Scholarlink

<p>In this study, we evaluated the in silico and in vitro anticancer activity of the antimicrobial peptide epinecidin-1 (Epi-1) and its lysine-substituted variants (Variant-1 (Var-1) &amp; Variant-2 (Var-2)). Computational docking demonstrated energetically favourable and structurally consistent interactions between the peptides and cancer-associated receptors (MerTK (PDB ID: 7OLX), EphA3 (PDB ID: 2QO9), TGF-β receptor I/ ALK5 (PDB ID: 3TZM), TrkA / NTRK1 (PDB ID: 4AOJ), and progesterone receptor (PDB ID: 1A28)), with distinct binding orientations and interaction profiles observed across the variants. Molecular dynamics simulation further substantiated these findings by confirming the stability of the selected receptor-ligand complex, with consistent root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), solvent-accessible surface area (SASA), and intermolecular hydrogen-bond interactions profiles indicating sustained interaction integrity under dynamic conditions. The in vitro antiproliferative activity of Epi-1 and its variants was assessed by MTT assays against A549, HeLa, HepG2, IMR-32 and MCF-7 cell lines. Both variants exhibited a two- to four-fold increase in cytotoxic activity compared with native Epi-1. We also evaluated the combinational activity of each peptide with doxorubicin, where peptide-doxorubicin treatments resulted in effective cancer cell killing at reduced drug concentrations relative to individual treatments, the Var-2 + doxorubicin combination reduced cancer cell survival to below 10% at a combined concentration of 1&#xa0;µg/mL (0.5&#xa0;µg/mL peptide + 0.5&#xa0;µg/mL doxorubicin), compared with ~ 30% survival in doxorubicin alone. This has been added alongside the existing two- to four-fold cytotoxicity enhancement of the variants over wild-type Epi-1, to better convey the impact of the synergistic response. While inducing selective lysis in cancer cells, the peptides exhibited minimal cytotoxicity toward non-cancerous HEK 293 cells, indicating improved therapeutic selectivity. DCFH-DA staining confirmed intracellular reactive oxygen species generation, and Acridine Orange/Ethidium Bromide (AO/EtBr) staining demonstrated apoptosis as the predominant mode of cell death across the cancer cell lines, although Var-1 induced necrotic death in HepG2 cells.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anticancer effects of alpha-helical peptide epinecidin-1 and its variants in combination with doxorubicin

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月22日

查看全文
  • Sivakumar Jeyarajan,
  • Sukumar Ranjith,
  • Atchyasri Anbarasu,
  • Indira Kandasamy,
  • Prahalathan Chidambaram,
  • Anbarasu Kumarasamy

摘要

In this study, we evaluated the in silico and in vitro anticancer activity of the antimicrobial peptide epinecidin-1 (Epi-1) and its lysine-substituted variants (Variant-1 (Var-1) & Variant-2 (Var-2)). Computational docking demonstrated energetically favourable and structurally consistent interactions between the peptides and cancer-associated receptors (MerTK (PDB ID: 7OLX), EphA3 (PDB ID: 2QO9), TGF-β receptor I/ ALK5 (PDB ID: 3TZM), TrkA / NTRK1 (PDB ID: 4AOJ), and progesterone receptor (PDB ID: 1A28)), with distinct binding orientations and interaction profiles observed across the variants. Molecular dynamics simulation further substantiated these findings by confirming the stability of the selected receptor-ligand complex, with consistent root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg), solvent-accessible surface area (SASA), and intermolecular hydrogen-bond interactions profiles indicating sustained interaction integrity under dynamic conditions. The in vitro antiproliferative activity of Epi-1 and its variants was assessed by MTT assays against A549, HeLa, HepG2, IMR-32 and MCF-7 cell lines. Both variants exhibited a two- to four-fold increase in cytotoxic activity compared with native Epi-1. We also evaluated the combinational activity of each peptide with doxorubicin, where peptide-doxorubicin treatments resulted in effective cancer cell killing at reduced drug concentrations relative to individual treatments, the Var-2 + doxorubicin combination reduced cancer cell survival to below 10% at a combined concentration of 1 µg/mL (0.5 µg/mL peptide + 0.5 µg/mL doxorubicin), compared with ~ 30% survival in doxorubicin alone. This has been added alongside the existing two- to four-fold cytotoxicity enhancement of the variants over wild-type Epi-1, to better convey the impact of the synergistic response. While inducing selective lysis in cancer cells, the peptides exhibited minimal cytotoxicity toward non-cancerous HEK 293 cells, indicating improved therapeutic selectivity. DCFH-DA staining confirmed intracellular reactive oxygen species generation, and Acridine Orange/Ethidium Bromide (AO/EtBr) staining demonstrated apoptosis as the predominant mode of cell death across the cancer cell lines, although Var-1 induced necrotic death in HepG2 cells.